NDATOPICALSPRAY
Approved
Apr 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
4/8 — Partial
TOPICORT (desoximetasone) by PharmaIN is corticosteroid hormone receptor agonists [moa]. Approved for plaque psoriasis in patients 18 years of age, older (), older and 1 more indications. First approved in 2013.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOPICORT (desoximetasone) is a potent topical corticosteroid spray approved for treating plaque psoriasis in adults 18 years and older. It works as a corticosteroid hormone receptor agonist, binding to glucocorticoid receptors to suppress immune function, inflammation, and protein regulation in affected skin. The spray formulation provides targeted delivery to psoriatic lesions with systemic absorption minimization.
LOE Approaching2.1 years to LOE
Product is 2.1 years from loss of exclusivity with limited commercial growth trajectory; small brand teams typically managing mature topical portfolios.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (4)
Worked on TOPICORT at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.